Tridestra

Indications: HRT for menopausal symptoms. Prevention of postmenopausal osteoporosis
Contra Indications: Cancer of breast, genital tract or other oestrogen-dependent carcinoma, undiagnosed vaginal bleeding or endometriosis. Active thrombophlebitis or thromboembolic disorders. Severe cardiac, hepatic or renal disease. Dubin-Johnson or Rotor syndromes. Pregnancy, lactation

Drug description: Estradiol valerate, white tablets; estradiol valerate/ medroxyprogesterone acetate, blue tablets; placebo, yellow tablets
Generic name: Estradiol [oestradiol], medroxyprogesterone acetate
Drug class description: Oestrogens / progestogens

History or increased risk of thromboembolic disorders. Mild chronic liver disease; monitor liver function every 8 to 12 weeks. Closely monitor patients with cholelithiasis, sclerosis, epilepsy, diabetes, hypertension, porphyria, uterine fibroids, tetany. Examine blood pressure, pelvic organs and breasts (particularly those with fibrocystic disease of the breast or a family history of breast cancer) before and regularly during treatment. If breakthrough bleeding is persistent, perform endometrial assessment, which may include biopsy

GI upset, nausea, vomiting, weight gain, breast tenderness and enlargement, breakthrough bleeding, headache, dizziness, impaired liver function, cholestatic jaundice, epistaxis, migraine, thromboembolic disorders, exacerbation of varicose veins, increased blood pressure, transient erythema, generalised pruritus. REASONS FOR IMMEDIATE DISCONTINUATION OF TREATMENT: Occurence of migraine-type headaches for the first time, frequent severe headaches, acute visual disturbances, signs of thrombophlebitis or thromboembolism, or any other possible prodromal symptoms of vascular occlusion. Rise in blood pressure. Jaundice. Pregnancy. Discontinue six weeks before major elective surgery and during immobilisation entailing risk of thrombosis